ATS leads €65m Series D round for German biotech firm

Ganymed pharmaceutical has now raised €117m from mostly German private equity firms to develop its cancer drugs pipeline.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this